Preface |
|
xv | |
|
|
1 | (16) |
|
What Is a Data Monitoring Committee (DMC)? |
|
|
1 | (1) |
|
|
2 | (1) |
|
DMC in Federal Government-Sponsored Clinical Trials versus Pharmaceutical Industry Clinical Trials |
|
|
3 | (1) |
|
|
4 | (1) |
|
|
5 | (1) |
|
Development of DMCs in the Pharmaceutical Industry |
|
|
5 | (1) |
|
Guidances---FDA, NIH, and ICH |
|
|
5 | (1) |
|
Other Vehicles for Patient Protection |
|
|
6 | (1) |
|
DMCs Place in the Drug Development Cycle |
|
|
6 | (6) |
|
Phases of Drug Development |
|
|
6 | (1) |
|
Limitations of a Clinical Program for Revealing Safety Issues |
|
|
6 | (3) |
|
Postmarket Safety Actions |
|
|
9 | (1) |
|
Role of DMCs in Exploratory and Confirmatory Trials |
|
|
9 | (2) |
|
Investigator-Sponsored Trials |
|
|
11 | (1) |
|
Open Label Extension Studies |
|
|
11 | (1) |
|
Pharmaceutical Industry Demographics |
|
|
12 | (1) |
|
|
12 | (1) |
|
Public versus Private Companies |
|
|
12 | (1) |
|
|
12 | (2) |
|
|
14 | (3) |
|
Organization of a Safety Monitoring Program for a Confirmatory Trial |
|
|
17 | (14) |
|
Members of the Safety Monitoring Team |
|
|
17 | (3) |
|
|
17 | (1) |
|
Data Monitoring Committee |
|
|
18 | (1) |
|
|
19 | (1) |
|
Institutional Review Board |
|
|
20 | (1) |
|
|
20 | (1) |
|
|
20 | (2) |
|
|
22 | (3) |
|
|
22 | (1) |
|
|
22 | (1) |
|
How Many Members Are Needed? |
|
|
22 | (1) |
|
|
23 | (1) |
|
|
23 | (1) |
|
Disclosure of DMC Membership |
|
|
23 | (2) |
|
|
25 | (1) |
|
From Where Are DMC Members Recruited? |
|
|
25 | (1) |
|
|
25 | (1) |
|
|
25 | (1) |
|
|
26 | (1) |
|
Liability and Indemnification |
|
|
26 | (1) |
|
|
27 | (1) |
|
Interdisciplinary Training |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
28 | (3) |
|
|
31 | (16) |
|
|
31 | (1) |
|
|
31 | (2) |
|
Orientation or Organizational Meeting |
|
|
32 | (1) |
|
|
33 | (1) |
|
|
33 | (1) |
|
|
33 | (5) |
|
Chair for Orientation Meeting |
|
|
33 | (1) |
|
Introduction of the Safety Monitoring Team |
|
|
33 | (1) |
|
Appointment of DMC Secretary |
|
|
33 | (1) |
|
Presentation of DMC Charter |
|
|
34 | (1) |
|
|
34 | (1) |
|
|
34 | (1) |
|
|
35 | (1) |
|
|
35 | (1) |
|
|
35 | (1) |
|
|
36 | (1) |
|
Review of Integrated Summary of Safety |
|
|
36 | (1) |
|
Policy on Review of Publications and Package Insert |
|
|
37 | (1) |
|
Formats for Tables, Listings, and Graphs |
|
|
37 | (1) |
|
Schedule First Data Review Meeting |
|
|
37 | (1) |
|
|
38 | (6) |
|
|
38 | (1) |
|
|
39 | (1) |
|
|
39 | (1) |
|
|
39 | (1) |
|
Update on Pending Action Items |
|
|
39 | (1) |
|
|
39 | (1) |
|
Sample Agenda for Open Session |
|
|
40 | (1) |
|
|
40 | (1) |
|
Scheduling of Next Meeting |
|
|
40 | (1) |
|
|
40 | (4) |
|
|
44 | (1) |
|
|
44 | (1) |
|
|
44 | (3) |
|
|
47 | (10) |
|
|
47 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
Serious Adverse Event Reporting Requirements |
|
|
48 | (1) |
|
|
49 | (2) |
|
|
49 | (1) |
|
|
49 | (1) |
|
|
49 | (1) |
|
|
50 | (1) |
|
|
51 | (1) |
|
|
51 | (1) |
|
|
51 | (1) |
|
Impact of Multinational Trials |
|
|
52 | (2) |
|
|
52 | (1) |
|
|
52 | (1) |
|
Medical/Surgical Practices Issues |
|
|
53 | (1) |
|
|
54 | (1) |
|
|
55 | (2) |
|
|
57 | (32) |
|
Goals of Statistical Analysis |
|
|
57 | (1) |
|
|
58 | (7) |
|
|
59 | (1) |
|
Graph of Cumulative Patient Enrollment by Month |
|
|
59 | (1) |
|
Graph of Cumulative Patient Exposure to Study Drug |
|
|
59 | (2) |
|
Treatment Emergent Adverse Events |
|
|
61 | (1) |
|
|
61 | (1) |
|
|
61 | (1) |
|
|
62 | (1) |
|
Incidence and Exposure Time Calculation |
|
|
62 | (1) |
|
Kaplan-Meier Time to First Occurrence |
|
|
63 | (1) |
|
Incidence at a Time Point after Treatment Start---Landmark Estimate |
|
|
63 | (1) |
|
Other Ways of Looking at Incidence |
|
|
64 | (1) |
|
|
65 | (1) |
|
Analysis Methods---Frequentist |
|
|
65 | (7) |
|
What Is Frequentist Analysis? |
|
|
65 | (1) |
|
|
65 | (3) |
|
|
68 | (1) |
|
|
68 | (1) |
|
Rate per 100 Patient Years |
|
|
68 | (1) |
|
|
69 | (1) |
|
|
70 | (2) |
|
Inference with Kaplan-Meier Landmark Estimates of Incidence |
|
|
72 | (1) |
|
Data Analysis without Statistics |
|
|
72 | (1) |
|
|
72 | (2) |
|
|
74 | (3) |
|
Analysis Methods---Likelihood |
|
|
77 | (5) |
|
Analysis Methods---Bayesian |
|
|
82 | (1) |
|
|
82 | (4) |
|
|
86 | (3) |
|
|
89 | (12) |
|
|
89 | (1) |
|
|
90 | (1) |
|
Knowledge of Treatment Assignment |
|
|
90 | (2) |
|
|
90 | (1) |
|
|
91 | (1) |
|
|
92 | (4) |
|
|
92 | (1) |
|
Knowledge of Treatment Assignment |
|
|
92 | (1) |
|
|
93 | (1) |
|
Spontaneous versus Solicited Adverse Event Collection |
|
|
93 | (1) |
|
|
94 | (1) |
|
Early Termination Due to Efficacy |
|
|
94 | (1) |
|
|
94 | (2) |
|
|
96 | (2) |
|
|
98 | (1) |
|
|
98 | (3) |
|
Data Monitoring Committee Decisions |
|
|
101 | (18) |
|
|
101 | (1) |
|
Decision-Making Environment |
|
|
102 | (1) |
|
Risk versus Benefit Analyses |
|
|
102 | (1) |
|
When a Safety Issue Arises |
|
|
103 | (5) |
|
|
104 | (1) |
|
``Dear Investigator'' Letter |
|
|
105 | (1) |
|
Modification of Informed Consent |
|
|
106 | (1) |
|
|
106 | (1) |
|
|
106 | (2) |
|
|
108 | (1) |
|
Information beyond the Present Trial |
|
|
108 | (2) |
|
|
110 | (2) |
|
|
112 | (1) |
|
Special Problems with Infant Pharma Companies |
|
|
112 | (1) |
|
|
113 | (1) |
|
|
113 | (6) |
|
|
119 | (16) |
|
|
119 | (1) |
|
|
120 | (6) |
|
|
120 | (1) |
|
Dropping a Dose or Treatment Group |
|
|
120 | (1) |
|
Adaptive Assignment to Treatment Group |
|
|
121 | (1) |
|
Changing Objectives: Superiority to Noninferiority |
|
|
121 | (1) |
|
Seamless Transition: Phase II to Phase III |
|
|
122 | (1) |
|
Change in Effect Size of Interest |
|
|
122 | (1) |
|
Further Thoughts on Adaptive Designs |
|
|
123 | (1) |
|
Real-Time SAE Reporting via the Internet |
|
|
124 | (1) |
|
|
125 | (1) |
|
|
125 | (1) |
|
|
126 | (1) |
|
Issues Due to Maturing of DMC Processes and Evolution of the Pharmaceutical Industry |
|
|
126 | (4) |
|
|
126 | (1) |
|
|
127 | (1) |
|
|
128 | (1) |
|
Internal Safety Review Committee |
|
|
128 | (1) |
|
|
129 | (1) |
|
Journal Policies Regarding Independent Review |
|
|
129 | (1) |
|
|
130 | (1) |
|
|
130 | (1) |
|
|
131 | (4) |
Appendix |
|
135 | (6) |
Glossary |
|
141 | (12) |
List of Abbreviations |
|
153 | (2) |
References |
|
155 | (12) |
Index |
|
167 | |